Skip to main content
Premium Trial:

Request an Annual Quote

DNA Manufacturer OriCiro Genomics Raises ¥800M in Series B Round

NEW YORK — OriCiro Genomics, a Japanese manufacturer of DNA for therapeutic and synthetic biology applications, said on Tuesday that it has raised ¥800 million ($7.3 million) in Series B funding and secured a ¥200 million long-term loan.

The financing round was led by University of Tokyo Edge Capital Partners and included ITOCHU Technology Ventures. The loan was provided by Japan Finance, a government-affiliated financial institution.

OriCiro was founded in late 2018 to develop and commercialize a proprietary technology for the cell-free assembly and amplification of large circular DNA. The so-called OriCiro Cell-Free Cloning System has applications in the pharmaceutical, diagnostic, agriculture, and food industries, according to the Tokyo-based company.

OriCiro said it will use the proceeds of the Series B round and loan to expand its manufacturing capabilities, advance its R&D, establish a US subsidiary, expand its intellectual property estate, and bring on new hires. It is also planning to launch a new plasmid DNA supply business aimed at the pharmaceutical and drug discovery markets.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.